Nivolumab
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
Exelixismonoclonal_antibodyPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Non-Clear Cell Renal Cell Carcinoma (nccRCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanzalintinib Exelixis | Phase 3 | BB |
Bms-907351 Exelixis | Phase 3 | B |
Atezolizumab Exelixis | Phase 3 | B |
PREDNISONE TABLETS Exelixis | Phase 3 | B |
Abiraterone Acetate Exelixis | Phase 3 | B |
Enzalutamide Exelixis | Phase 3 | B |
Ipilimumab Exelixis | Phase 1 | CC |
Relatlimab Exelixis | Phase 1 | CC |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →